Abstract
Bladder cancer is one of most common malignant urinary tract tumor types with high incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder cancer followed by intravesical instillation of chemotherapy is the standard treatment approach to minimize recurrence and delay progression of bladder cancer. However, conventional intravesical chemotherapy lacks selectivity for tumor tissues and the concentration of drug is reduced with the excretion of urine, leading to frequent administration and heavy local irritation symptoms. While nanomedicines can overcome all the above shortcomings and adhere to the surface of bladder tumors for a long time, and continuously and efficiently release drugs to bladder cancers. The rapid advances in targeted therapy have led to significant improvements in drug efficacy and precision of targeted drug delivery to eradicate tumor cells, with reduced side-effects. This review summarizes the different available nano-systems of targeted drug delivery to bladder cancer tissues. The challenges and prospects of targeted therapy for bladder cancer are additionally discussed.
Highlights
Bladder cancer (BC) is the ninth most common urinary tract cancer type worldwide
Bacillus Calmette-Guérin (BCG) has long been approved as an immunotherapeutic agent (GuallarGarrido and Julian, 2020) and its potential mechanism of action of BCG is that the absorption, internalization and subsequent induction of cytokines produced by BCG after intravesical instillation induce adaptive immunity and anti-tumor effects, thereby reducing the recurrence and progression of bladder cancer (Pettenati and Ingersoll, 2018; Han et al, 2020)
Folic acid (FA, known as vitamin B9) is a critical nutrient for growth and development of organisms that plays an indispensable role in DNA methylation, biosynthesis and repair
Summary
Bladder cancer (BC) is the ninth most common urinary tract cancer type worldwide. In Western countries, the incidence of bladder cancer is different between genders, and the life time risk of bladder cancer is approximately 1.1 and 0.27% in men and women, respectively (Lenis et al, 2020). Targeted-Nanomedicines for Bladder Cancer Therapy chemotherapy to reduce recurrence and delay or even prevent progression to muscle-invasive disease. Bacillus Calmette-Guérin (BCG) has long been approved as an immunotherapeutic agent (GuallarGarrido and Julian, 2020) and its potential mechanism of action of BCG is that the absorption, internalization and subsequent induction of cytokines produced by BCG after intravesical instillation induce adaptive immunity and anti-tumor effects, thereby reducing the recurrence and progression of bladder cancer (Pettenati and Ingersoll, 2018; Han et al, 2020). With advances in tunable optical, magnetic, electronic, and biological properties, nanomaterials can be developed with different sizes, shapes, chemical compositions, and surface chemical characteristics (Peer et al, 2007; Xia et al, 2009) Based on their multiple beneficial features, nanomaterials have significant potential as a new generation of drug delivery vehicles. CAT-TCPP/FCS CS-PCL (PLL−P (LP-co-LC) P (LP-co-LC) FA-conjugated Au@TNA/MB Bld-1-KLA MSNs@PDA-PEP PLZ4-PNP PLZ4-DNR/PTX MPI/F-PEI PCL-b-PEO C225 antibody siRNA@CS-HAD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
